Indication
Eosinophilic Myeloid Neoplasms
1 clinical trial
2 products
Clinical trial
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeStatus: Recruiting, Estimated PCD: 2025-01-01
Product
ImatinibProduct
Ruxolitinib